American journal of nuclear medicine and molecular imaging最新文献

{"title":"CNN-based detection of pediatric lymphoma on whole body [¹⁸F]FDG-PET/MRI.","authors":"Shashi B Singh, Yashas Ullas Lokesha, Hongzhi Wang, Michael Joseph Barrow, Ricarda von Kruechten, Iryna Vasyliv, Amir Hossein Sarrami, Joy Tzung-Yu Wu, Lucia Baratto, Lisa Christine Adams, Hyun Gi Kim, Jason Wong, Tie Liang, Sergios Gatidis, Tanveer Syeda-Mahmood, Heike E Daldrup-Link","doi":"10.62347/RSDQ2273","DOIUrl":"10.62347/RSDQ2273","url":null,"abstract":"<p><p>We assessed the performance of a deep convolutional neural network (CNN) in detecting pediatric lymphoma lesions on [¹⁸F]FDG-PET/MRI. We evaluated CNN's sensitivity, specificity, percentage agreement, and processing time compared to the interpretations of a pediatric radiologist and a second-year radiology resident. In this retrospective study, a CNN was trained on annotated [¹⁸F]FDG-PET/MRI scans from 53 pediatric lymphoma patients and tested on 30 additional scans. The CNN and two human readers recorded the presence of lesions in five anatomical regions. An additional pediatric radiologist and a nuclear medicine physician determined the reference standard. The sensitivity and specificity of the CNN were compared with those of human readers using the McNemar test, and the detection time of the CNN and human readers was compared using the Wilcoxon signed-rank test. The CNN demonstrated higher sensitivity (84.6%) and specificity (93.7%) than the radiology resident (69.2%, P=0.023; 81.5%, P<0.001), but lower than the pediatric radiologist (98.7%, P<0.001; 99.5%, P<0.001). The CNN achieved 83% agreement with the reference standard (95% CI: 79%-87%), higher than the resident's 63% (95% CI: 59%-69%) but lower than the pediatric radiologist's 94% (95% CI: 92%-97%). The median values and interquartile ranges for the time taken (in minutes) were 4 (3, 5) for the CNN, 8 (7, 10) for the pediatric radiologist, and 15 (9, 20) for the radiology resident. The sensitivity, specificity, and percentage agreement of the CNN were higher than those of a radiology resident but lower than those of a pediatric radiologist. The CNN readout was significantly faster compared to both human readers.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"16 1","pages":"55-62"},"PeriodicalIF":1.7,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13003233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using multimodal PET+MR data as conditional generative adversarial network inputs improves pseudo-CT and attenuation correction estimates for brain PET/MR.","authors":"Jonathan Fisher, Emily Anaya, Garry Chinn, Craig S Levin","doi":"10.62347/BONK5634","DOIUrl":"10.62347/BONK5634","url":null,"abstract":"<p><p>To obtain qualitatively and quantitatively accurate positron emission tomography (PET) images, the recorded PET emission data must be corrected for photon attenuation. Attenuation correction (AC) factors are typically estimated from X-ray computed tomography (CT) data acquired during an integrated PET/CT study. Estimating these factors from magnetic resonance (MR) data in an integrated PET/MR scanner is challenging, as MR images don't provide direct information about annihilation photon attenuation. Conditional generative adversarial networks (cGANs) have shown promising results for both emission-based and MR-based AC. This study explored whether combining these approaches could further improve brain PET AC accuracy. Thirty-five patients who received same-day whole-body PET/MR and PET/CT scans participated in this study. The non-attenuation-corrected and non-scatter-corrected (NASC) PET, MR, and CT reconstructed head regions were cropped and automatically co-registered. Four networks were trained to translate NASC PET and MR images into pseudo-CTs. Three used single-modality input, and the fourth used multi-modality. The multi-modality cGAN produced significantly better pseudo-CTs vs. the single-modality cGANs, with an average structural similarity index (SSIM) and dice similarity coefficients for bone, soft-tissue, and air of 0.865±0.001, 0.715±0.002, 0.915±0.001, and 0.567±0.004, respectively, vs. 0.841±0.001, 0.660±0.003, 0.894±0.001, and 0.524±0.005, for the single-modality cGANs with the best results. When comparing the AC PET reconstructed images, all cGANs outperformed the clinical atlas-based method used in commercially available PET/MR systems, and, as expected, the multi-modal cGAN achieved the highest quality results with average SSIM, and peak signal-to-noise ratio of 0.9987±0.0001, and 50.0±0.4, respectively, vs. 0.9913±0.0024, and 44.3±0.3 for the atlas method.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"16 1","pages":"44-54"},"PeriodicalIF":1.7,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13003229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of I-131 thyroid remnant uptake in patients with thyroid cancer.","authors":"Elaheh Amini, Catherine Kim, Asya S Al-Busaidi, Ran Klein, Wanzhen Zeng","doi":"10.62347/SBTR2479","DOIUrl":"10.62347/SBTR2479","url":null,"abstract":"<p><p>Radioiodine ablation is commonly performed after thyroidectomy for well-differentiated thyroid cancer (DTC). This study aimed to quantify thyroid remnant uptake in standardized uptake values (SUV) and evaluate its correlation with post-therapy Thyroglobulin (Tg) levels across different risk groups. We retrospectively quantified SUV uptake with attenuation, scatter, and resolution recovery corrections on post-therapy SPECT/CT in thyroid cancer patients referred to our centre between 2015 and 2017. Thyroid remnant was segmented with a maximum SUV of 0.5 as the threshold and total thyroid remnant uptake (SUV_total) was obtained. Patients were stratified into low-intermediate, high-intermediate, and high-risk groups based on clinical risk and therapeutic dose. The primary outcome was the correlation between SUV_total and post-therapy Tg levels. The cohort consisted of 174 adults (age: 50.7±16.0 yr, F:M=110:64). Moderate correlations were found between SUV_total and Tg levels in low-intermediate and high-intermediate groups (Spearman's <i>ρ</i>=0.65, P<0.001; <i>ρ</i>=0.61, P<0.001, respectively). No significant correlation was found in the high-risk group (<i>ρ</i>=0.12, P=0.33). Stimulated Tg levels increased (median Tg: 4, 7, and 13 pmol/L) and thyroid remnant uptake decreased (median SUV_total: 272, 51, and 33) across the low-intermediate, high-intermediate, and high risk groups. In conclusion, this study shows good correlations between the thyroid remnant uptake and thyroglobulin in subgroups of patients with low-intermediate and high-intermediate risk DTC. The rationales for lack of significant correlation in the high-risk group DTC were discussed. Thyroid uptake quantification may serve as a feasible substitute for Tg measurements in post-ablation follow-up, offering potential for predicting disease recurrence.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 6","pages":"251-261"},"PeriodicalIF":1.8,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12816826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146016852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare presentation of intraparenchymal renal artery aneurysm disguised as renal cell carcinoma: a case report and literature review.","authors":"Qing-Ke Chen, Qian Zou, Tao-Tao Sun, Feng-Lian Jiang, Lu Wang, Jun-Hong Fan","doi":"10.62347/JPNL3964","DOIUrl":"10.62347/JPNL3964","url":null,"abstract":"<p><p>Renal artery aneurysms (RAAs) are rare vascular abnormalities that are often detected incidentally, as most patients are asymptomatic and the lesions are discovered during imaging for unrelated conditions. Differentiating intraparenchymal RAAs (IPRAAs) from renal tumors using non-invasive imaging techniques remains challenging. Misdiagnosis as a renal malignancy, such as renal cell carcinoma (RCC), poses a significant risk of catastrophic hemorrhage if inadvertently subjected to biopsy or surgical procedures. We reported the case of a 75-year-old female with an IPRAA that mimicked RCC on contrast-enhanced computed tomography (CECT). However, a suspicious feeding artery to the renal mass was identified on computed tomography angiography (CTA) images. Further evaluation with positron emission tomography/magnetic resonance imaging (PET/MR) suggests the diagnosis of IPRAA. This was confirmed by digital subtraction angiography (DSA), and the aneurysm was successfully treated with transcatheter embolization. This case highlights the importance of including IPRAA in the differential diagnosis of renal masses and emphasizes the need for careful imaging evaluation to avoid potentially life-threatening complications from misdiagnosis.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 6","pages":"272-277"},"PeriodicalIF":1.8,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12816824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146016847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current landscape and clinical progress of targeted alpha radioimmunotherapy.","authors":"Owen C Booth, Karena R Dhamecha, Oluwaseyi M Oderinde, Qi-Huang Zheng","doi":"10.62347/GETQ4987","DOIUrl":"10.62347/GETQ4987","url":null,"abstract":"<p><p>Theranostics is an interesting area of cancer research that describes the use of radiotracers to first diagnose and then treat cancer. By coupling a radioisotope to an agent that selectively targets malignant cells, one can distribute focused radiation to disease sites. There are a variety of different radiopharmaceutical vectors that have been utilized in this way, such as peptides, small molecules and antibodies. Because antibodies bind to highly specific antigens, radioimmunotherapy (RIT) offers a promising route to precisely targeted treatments with reduced systemic toxicity compared to conventional radiotherapy. Beta (β)-emitting isotopes (e.g., ¹³¹I, ⁹⁰Y) have been more commonly coupled in RIT, but the use of alpha (α)-emitters (e.g., ²²⁵Ac, ²¹²Pb), for RIT (α-RIT) has rising popularity due to their shorter tissue range and higher linear energy transfer. These characteristics decrease off-target effects in neighboring tissues and increase tumor cell destruction, respectively. However, there are several challenges to RIT. The production of daughter isotopes from α decay makes dosimetric assessments difficult and could potentially cause off target toxicities. Additionally, whole antibodies tend to accumulate in liver tissue and have long biological clearance times, which may cause excess radiation to the blood, marrow and liver. Yet, there are a variety of α-RIT agents currently in development to treat prostate cancer, hematologic malignancies, and other solid tumors. Many agents show promise, like ²²⁷Th-epratuzumab, a CD22-targeting antibody used in the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). While notoriously deadly and difficult to treat, the disease control rate in patients with R/R AML taking ²²⁷Th-epratuzumab was 38%. Like many α-RIT therapies, follow-up studies are needed to continue to improve efficacy. Strategies to widen the therapeutic indices of these agents have been investigated such as pretargeting, use of antibody fragments, chelator optimization and combination therapies. This review describes the current landscape and clinical progress of targeted α radioimmunotherapy.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 6","pages":"236-250"},"PeriodicalIF":1.8,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12816825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146016827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results from a prospective registry of ¹⁸F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PET.","authors":"Steven Blinka, Risa L Wong, Sarah K Holt, Ethan Lo, Heather H Cheng, Nathan Conrad, Hannah Loesch, Andrea E Toulouse, Michael Lai, Andrew C Hsieh, Petros Grivas, Todd Yezefski, Jonathan L Wright, Michael T Schweizer, Robert B Montgomery, Delphine L Chen, Jing Zeng, Daniel W Lin, Evan Y Yu","doi":"10.62347/IAWB9145","DOIUrl":"10.62347/IAWB9145","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;&lt;sup&gt;18&lt;/sup&gt;F-Fluciclovine positron emission tomography (PET) was FDA-approved in the U.S. in 2016 and was the most sensitive imaging modality for prostate cancer (PC) until the approval of prostate-specific membrane antigen (PSMA) PET in 2020. However, providers' reasons for ordering &lt;sup&gt;18&lt;/sup&gt;F-Fluciclovine PET/CT (FluPET) in practice and impact on patient care remain poorly defined. This prospective registry at a tertiary academic center describes patterns of FluPET use and outcomes prior to the FDA approval of PSMA PET in December 2020.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Providers ordering FluPET for patients with PC were surveyed before, ≤2 weeks after, and ≥1 year after imaging to assess reasons for obtaining FluPET, projected treatment plan, changes in plan due to FluPET findings, and toxicity attributable to the change in treatment plan. Baseline patient characteristics, FluPET results, and longitudinal outcomes were collected.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Between 12/2018-09/2021, 62 patients with localized PC (8.1%), biochemical recurrence (BCR; 80.6%), non-metastatic castration-resistant PC (CRPC) (3.2%), metastatic castration-sensitive PC (3.2%), or metastatic CRPC (4.8%) were enrolled and underwent FluPET. Most scans (90.3%) were performed prior to the FDA approval of PSMA PET 12/2020. FluPET was most often obtained to guide local salvage or metastasis-directed therapies (90.3%); other reasons (non-exclusive) were initial staging (9.6%) or clarifying equivocal lesions from other imaging (9.6%). FluPET detected ≥1 PC lesion in 74.2% of patients. After FluPET, 48.4% of providers reported changing treatment plans, which was more likely when FluPET was positive (60.9% vs 12.5%, P&lt;0.001), and often involved initiation of systemic therapy (19.4%). Treatment changes were reported in 57% of patients with BCR1 and 48.2% of patients with BCR2. In contrast, only 20% of patients with distant metastatic disease had a change in treatment. Among patients in the BCR1 and BCR2 cohort, treatment plan changes were associated with a median time to next treatment that was not reached after a median follow-up of 67.6 months. There was no statistically significant difference in overall survival between patients with biochemical recurrence (BCR) who did and did not have a treatment plan change. A year after FluPET, reported potential toxicities from treatment plan changes were minimal.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;FluPET was utilized across the disease spectrum of PC, primarily to guide local salvage or metastasis-directed therapies, given its improved sensitivity for detecting prostate bed recurrence due to the slow physiologic excretion of &lt;sup&gt;18&lt;/sup&gt;F-fluciclovine. Notably, a positive FluPET frequently prompted initiation of systemic therapy; however, the clinical benefit of such management remains uncertain. Moreover, providers often selected multiple, sometimes conflicting, treatment plans following FluPET, re","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 6","pages":"262-271"},"PeriodicalIF":1.8,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12816827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146016893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatostatin receptor PET-guided treatment and artificial intelligence applications in meningioma: a comprehensive review.","authors":"Jaskeerat Gujral, Om H Gandhi, Amir A Amanullah, Shashi B Singh, Cyrus Ayubcha, Thomas J Werner, Mona-Elisabeth Revheim, Abass Alavi","doi":"10.62347/LYAT6783","DOIUrl":"10.62347/LYAT6783","url":null,"abstract":"<p><p>Meningiomas are the most common primary intracranial tumors, with treatment involving resection and radiation therapy. However, therapeutic options are limited for recurrent or progressive disease, particularly in higher World Health Organization (WHO) grade tumors. Somatostatin receptor (SSTR) expression in meningiomas has opened new therapeutic opportunities as the differential SSTR2 overexpression permits molecular targeting using radiolabeled somatostatin analogs. PRRT offers promising therapeutic efficacy in select meningioma patients, with clinical responses strongly correlated to WHO tumor grade and SSTR expression levels. Combining SSTR PET imaging, to evaluate receptor density, with radiomic analysis can reveal tumor heterogeneity patterns and quantitative imaging features that can guide clinical decision-making and monitor treatment response. Integrating machine learning and artificial intelligence (AI) into clinical workflows offer novel approaches to apply quantitative SUV parameters, image texture features, and histopathologic data in order to identify patients with WHO grade II and III meningiomas at greater risk of tumor recurrence. Given the heterogeneity in imaging and treatment protocols across institutions and the limited number of PRRT-treated meningioma cohorts, future research should prioritize prospective, multicenter studies that integrate histologic and molecular imaging data to refine patient selection strategies and establish PRRT's role within personalized, precision cancer treatment paradigms.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 6","pages":"223-235"},"PeriodicalIF":1.7,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12816823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146016998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From lutetium to terbium: a new era in PSMA-targeted radioligand therapy for mCRPC patients.","authors":"Steven H Liang","doi":"10.62347/JAXA6254","DOIUrl":"10.62347/JAXA6254","url":null,"abstract":"<p><p>Terbium-161 (¹⁶¹Tb) is emerging as a promising theranostic radionuclide for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC). Compared with lutetium-177 (¹⁷⁷Lu), ¹⁶¹Tb emits additional high-linear energy transfer Auger and internal conversion electrons, enabling superior tumor cell kill in micrometastatic disease. Early clinical studies demonstrate favorable safety, dosimetry, and efficacy profiles for ¹⁶¹Tb-labeled PSMA ligands. Ongoing trials and production advancements are critical to fully realizing the therapeutic potential of ¹⁶¹Tb-based RLT.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 5","pages":"219-222"},"PeriodicalIF":1.8,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12629902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145585942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular tumor volume on PSMA PET/CT is an independent imaging biomarker associated with progression-free survival in patients with oligorecurrent prostate cancer.","authors":"Monica Cheng, Umar Mahmood, Nathaniel D Mercaldo, Shadi A Esfahani, Thomas Ng, Xin Gao, Jason A Efstathiou, Pedram Heidari","doi":"10.62347/NCJF9597","DOIUrl":"10.62347/NCJF9597","url":null,"abstract":"<p><p>The purpose of this study is to evaluate the PSMA PET imaging parameters in association with outcomes among patients with oligorecurrent prostate cancer. This retrospective single-center study included 101 patients (median age 71; interquartile range 65-75) with biochemically recurrent prostate cancer who underwent PSMA PET between May 2021 and May 2022, revealing 5 or fewer sites of metastases (oligometastatic disease). Multiple variables including maximum standardized uptake value (SUV_max), mean standardized uptake value (SUV_mean), and molecular tumor volume (MTV) were measured and analyzed on a per-patient basis, along with total MTV and molecular tumor burden (MTB). Multivariable Cox proportional-hazards regression models were used to identify factors associated with progression-free survival (PFS). PSMA PET revealed a total of 216 lesions across all patients, of which 134 (62.0%) involved the lymph nodes and 56 (25.9%) involved the bone. A total of 61 (60.4%) patients received combined metastasis-directed and hormone therapy, and 40 (39.6%) received hormone therapy only. The median subsequent follow-up from PSMA PET detection of oligorecurrent disease was 18.2 months (IQR 10.3-25.0). MTV on PSMA PET was associated with worse PFS (hazard ratio: 1.05, 95% CI 1.00-1.11; P = 0.04). Molecular tumor volume on PSMA PET is associated with worse clinical outcomes in patients with oligorecurrent prostate cancer.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 5","pages":"193-199"},"PeriodicalIF":1.8,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12629906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145585939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PARP-targeted molecular imaging for noninvasive diagnosis and surgical guidance in basal cell carcinoma.","authors":"Steven H Liang","doi":"10.62347/BEJG4271","DOIUrl":"10.62347/BEJG4271","url":null,"abstract":"<p><p>Poly(ADP-Ribose) Polymerase 1 (PARP1) is a key DNA repair enzyme and therapeutic target in cancer, with overexpression observed in several cancers, including basal cell carcinoma (BCC). Conventional diagnostic methods for BCC lack specificity and are invasive, highlighting the need for noninvasive alternatives. PARP-targeted molecular imaging, particularly with fluorescence probes, has shown strong potential for tumor detection and real-time visualization. PARPi-FL, a fluorescent derivative of Olaparib, enables rapid, specific, and high-contrast imaging of BCC in preclinical and <i>ex vivo</i> human studies. Optimized application protocols confirm its safety and translational promise for noninvasive diagnosis and image-guided surgery.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 5","pages":"208-211"},"PeriodicalIF":1.8,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12629905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145585934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}